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ABSTRACT  
A 
conflict of interest is defined as “a set of conditions in which professional judgment concerning a primary 
 interest (such as a patient’s welfare or the validity of research) tends to be unduly influenced by a secondary interest 
(such as financial gain)” [Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329(8):573–
576]. Because financial conflict of interest (fCOI) can occur at different stages of a study, and because it can be difficult 
for investigators to detect their own bias, particularly retrospectively, we sought to provide funders, journal editors 
and other stakeholders with a standardized tool that initiates detailed reporting of different aspects of fCOI when the 
study begins and continues that reporting throughout the study process to publication. We developed a checklist using 
a 3-phase process of pre-meeting item generation, a stakeholder meeting and post-meeting consolidation. External 
experts (n = 18), research team members (n = 12) and research staff members (n = 4) rated or reviewed items for 
some or all of the 7 major iterations. The resulting Financial Conflicts of Interest Checklist 2010 consists of 4 sections 
covering administrative, study, personal financial, and authorship information, which are divided into 6 modules and 
contain a total of 15 items and their related sub-items; it also includes a glossary of terms. The modules are designed 
to be completed by all investigators at different points over the course of the study, and updated information can be 
appended to the checklist when it is submitted to stakeholder groups for review. We invite comments and suggestions 
for improvement at www.openmedicine.ca/fcoichecklist and ask stakeholder groups to endorse the use of the checklist. 
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A 
conflict of interest is defined as “a set of condi-
tions in which professional judgment concerning
  a primary interest (such as a patient’s welfare or 
the validity of research) tends to be unduly influenced 
by a secondary interest (such as financial gain).”  1 Con-
flict of interest in biomedical research is a complex is-
sue that has received a great deal of attention. The focus 
of the 2009 Institute of Medicine report on conflict of 
interest highlights the importance of this issue.2 When 
there are financial interests in research studies there is 
concern that these relationships may influence research 
outcomes.3  Despite the importance of this issue, there 
is considerable variability in the way that these relation-
ships have been reported.2,3 To protect research partici-
pants and maintain public trust in research, it is impor-
tant that potential financial conflicts of interest (fCOIs) 
are disclosed and steps are taken, where indicated, to 
manage their effects.2  
Investigators may not always recognize their own po-
tential conflicts of interest and therefore would benefit 
from a structured method of documenting and report-
ing  fCOI  to  stakeholders  for  assessment  purposes.2,4 
When we began this project in January 2007, various 
fCOI  reporting  disclosures  were  required  by  different 
stakeholder groups such as funders,5 academic institu-
tions,6 and journal editors.7 These disclosures were not 
coordinated and were typically collected using different 
reporting  formats  (e.g.,  fCOI  forms,  fCOI  statements). 
This meant that investigators might need to complete 
multiple different conflict of interest reporting disclo-
sures for their study in order to meet the needs of differ-
ent stakeholders. 
We sought to provide stakeholders with a single struc-
tured checklist that contains detailed information about 
different aspects of fCOI. Further, we placed this infor-
mation within the context of a specific clinical research 
study to facilitate assessment of the potential impact of 
the  financial  relationship  on  the  research.  By  using  a 
prospective format, potential conflicts can be identified 
at an early stage in the research process and managed 
where required. The checklist is initiated when the study 
begins and is updated throughout the study process to 
publication. Although we designed the checklist for clin-
ical research studies, we recognize that other types of 
studies have the potential to be influenced by fCOIs.
  Developing the Financial Conflicts of Interest 
Checklist 2010 
We developed the checklist using a 3-phase process of 
pre-meeting item generation, a stakeholder meeting, and 
post-meeting consolidation. This process, shown in Fig-
ure 1, was adapted from one described in a recent report 
on  developing  health  research  reporting  guidelines.8 
Contributors  to  the  development  of  this  checklist  are 
listed in the Acknowledgments.
Pre-meeting  item  generation.  The  checklist  items 
were  generated  initially  by  our  research  team,  whose 
members have expertise in research, ethics boards, law 
and  policy,  trial  registration,  research  administration, 
clinical  research  and  research  guideline  development—
specifically  the  Consolidated  Standards  of  Reporting 
Trials (CONSORT) and Enhancing QUAlity and Transpar-
ency Of health Research (EQUATOR) Network—and were 
based primarily on the published literature. We identified 
potential  items  from  international  initiatives  targeting 
specific aspects of fCOI. For example, items related to trial 
registration were derived from the World Health Organ-
ization trial registration initiative,9 and items related to 
roles in manuscripts were drawn from the International 
Committee of Medical Journal Editors (ICMJE) guide-
lines on authorship in medical publishing4,  7 and the World 
Association of Medical Editors guidelines on authorship.10       
After compiling an initial list of 15 items and 92 sub-
items, we reviewed it using 3 groups: external experts 
(n  =  18)  with  expertise  in  trial  registration,  research 
guideline  development  (CONSORT,  EQUATOR),  ethics 
review,  government  administration  policy,  health  law, 
medical journals and media; members of the research 
team (n = 12); and members of our research staff (n = 4). 
Research staff members were included to provide a per-
spective  from  non-experts  with  experience  in  the  re-
search process.  
Reviewers were asked to rate the importance of each 
of the items using a 5-point scale (1 = least important, 
5 = most important) and to provide free-text suggestions 
for improving them. On the basis of these responses, we 
developed a second version of the checklist and, 1 month 
later, sent it to the participants for review. Not all of the 
reviewers were available for both rating sessions: 29 pro-
vided feedback to version 1, and 24 provided feedback to 
version 2. 
Stakeholder meeting. A total of 28 people participat-
ed in a day-long stakeholder meeting in October 2007 
in Toronto, Ontario, Canada. In attendance were 11 re-
search team members and 4 research staff; 13 external 
experts participated using web-teleconference connec-
tions from 4 countries. We presented draft version 3 of 
the checklist for item discussion and identified areas for 
revision.  The  meeting  was  organized  into  4  thematic Open Medicine 2010;4(1):e71
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sessions reflecting the requirements 
and  concerns  of  major  stakeholder 
groups  (clinical  trial  registry  users, 
journal editors, funders and policy-
makers, and legal and ethics review 
board  representatives).  Each  exter-
nal expert participated in 1 session 
based on his or her area of expertise. 
Each session began with an overview 
of the checklist project, followed by a 
description of the particular themat-
ic area; the session chair then led a 
discussion focusing on items that re-
ceived discrepant ratings in the pre-
meeting reviews.  
Post-meeting consolidation. The 
post-meeting  consolidation  phase 
involved 3 steps. First, the research 
team incorporated the changes sug-
gested  at  the  stakeholder  meeting 
into  draft  version  4  of  the  check-
list—including  dividing  the  items 
into  modules—and  then  pilot-tested 
this version for usability with a small 
group of 6 investigators. We also cre-
ated an example document showing 
examples  of  good  reporting,  an  ex-
planation  document  providing  evi-
dence  and  rationales  for  the  items, 
and an interactive PDF version of the 
checklist.  
Second,  the  research  team  met 
in Toronto for a 1-day consolidation 
meeting in March 2009 and reviewed 
the checklist by module and item. We 
reworded and reorganized items for 
greater  clarity,  decided  to  create  a 
glossary  to  facilitate  shared  under-
standing and usage of key terms used 
in  the  items,  and  discussed  how  to 
improve the usability of the PDF ver-
sion. We also had further discussions 
on how we envisioned the checklist 
would be implemented in practice.
In the third step of the post-meet-
ing  consolidation  phase,  we  incor-
porated the most recent changes into 
draft version 5 of the checklist. Def-
initions for the glossary terms were 
Figure 1: Financial Conflicts of Interest Checklist 2010  
development process 
Checklist version 1 
(September 2007)
15 items, 92 sub-items Rating of all items using a 5-point scale  
(1 = least important, 5 = most important) by 29 reviewers:
Mean score 3.1–4.8 points
71/92 (77%) items with mean score ≥ 4.0 
Rating of all items using a 5-point scale  
(1 = least important, 5 = most important) by 24 reviewers:
Mean score 3.1–5.0 points
60/65 (92%) items with mean score ≥ 4.0
Checklist version 2 
(October 2007)
13 items, 65 sub-items
Pre-meeting item generation
Checklist version 3 
Stakeholder meeting 
(October 2007)
13 items, 74 sub-items
Participants:  
11 research team members
13 external experts
4 research staˆ
• Example document created
• Explanation document created
• Interactive PDF version created
Stakeholder meeting
Checklist version 4 
(April 2008)
8 modules, 18 items, 
72 sub-items
Checklist version 5 
(March 2009)
7 modules, 14 items, 
80 sub-items
Initial usability survey   
Research team meeting (March 2009)
Final usability survey
Interactive PDF version of Checklist 
Post-meeting consolidation
Checklist version 6 
(May 2009)




6 modules, 15 items, 
80 sub-items
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incorporated as roll-over pop-ups attached to the terms 
in the PDF. We revised the corresponding example and 
explanation  documents  and  pilot-tested  the  checklist 
again for usability. After successive revisions for con-
sistency and clarity to the draft version 6 checklist and 
the corresponding interactive PDF, version 7 of the Fi-
nancial Conflicts of Interest Checklist 2010 was created.
Ethical review and approval of the checklist process 
was  obtained  from  the  Baycrest  Centre  and  Women’s 
College Research Institute Ethics Board, where the prin-
cipal investigator was located. 
The Financial Conflicts of Interest Checklist 2010
The Financial Conflicts of Interest Checklist 2010 (Table 
1) consists of a 15-item form and a glossary of terms with 
definitions derived from sources obtained from our lit-
erature review. The checklist is also available as an inter-
active PDF (see the online Appendix). A feature of the PDF 
format is that it uses “skip logic”; it presents to investiga-
tors only selections relevant to them at the time of check-
list completion based on their answers. The glossary is 
incorporated into the PDF through pop-ups that provide 
the definition when a mouse rolls over a glossary term. 
The 4 sections of the checklist cover administrative 
information, study information, personal financial infor-
mation and authorship information. These sections are 
divided into 6 modules containing a total of 15 items and 
their related sub-items. The Administrative Information 
section contains module A, which compiles administra-
tive information about the study and investigator, and 
the date(s) when the checklist was first filled out and 
subsequently  updated.  The  Study  Information  section 
contains modules B to D, which create a funder profile, 
contract profile, and study team and funder relationship 
profile respectively. The Personal Financial Information 
section contains module E, which creates a financial pro-
file for each investigator of the study and author of any 
study publication. Finally, the Authorship Information 
section contains module F, which creates an authorship 
profile for each author involved in manuscript prepara-
tion. We have also provided an example document (Table 
2), which presents examples of good reporting, and an 
explanation document (Box 1), which presents rationales 
and evidence for each of the 6 modules.  
The checklist was designed as a living document that 
is updated as the study progresses. In general, sections 
1 to 3 will be completed at study initiation and updated 
as necessary (for example, section 3, the Personal Fi-
nancial Information section, would require updating if 
the  investigator’s  financial  profile  changed);  section  4 
will be completed when a manuscript is being prepared 
for publication. We anticipate that updated information 
would be appended to the originally completed checklist 
to maintain a permanent record of information related 
to fCOI throughout the course of the study.   
We recognize that clinical research and, in particular, 
clinical trials are generally conducted by a team of inves-
tigators. We recommend that each investigator independ-
ently complete the entire checklist. When the checklist is 
submitted to a stakeholder for review, the person most 
knowledgeable about the study, such as the overall study 
official (in the case of clinical trials) or study guarantor 
(in the case of a manuscript submission), would collate 
sections of the checklist that have shared information 
(i.e., module A: Administrative Profile, module B: Fund-
er Profile and module C: Contract Profile).  
We pilot-tested the checklist twice during the post-
meeting consolidation phase. Of the 17 participants in 
these usability surveys, 13 (76%) had served as an in-
vestigator in a randomized trial. Eleven (65%) respond-
ents reported no difficulty in answering the questions. 
Although the checklist should be completed at different 
stages of the study process, for the purposes of deter-
mining usability respondents were asked to estimate the 
time required to complete the entire checklist: 16 (94%) 
required less than 20 minutes. 
Discussion
We have created a checklist that aims to promote trans-
parency at all stages of the research and publication pro-
cess. An important feature of our checklist is that, as a 
record completed by investigators as the study evolves, it 
can be given to the various stakeholders who are involved 
at different stages of the clinical research process—fund-
ing agencies, research ethics boards, trial registries, re-
search administrators and journal editors—which is a 
more consistent, efficient and effective approach than 
providing each group with separate, disjointed disclo-
sures. As well, since the type of fCOI information re-
quired by stakeholders varies substantially, use of the 
checklist may help standardize the information. 
Prospective completion of the checklist means that 
there is an ability to elicit fCOI disclosures throughout 
the  study’s  “life  stages”  (e.g.,  from  study  inception  to 
dissemination) and to maintain a public record of this 
information for its duration. There are 2 benefits to iden-
tifying potential fCOI situations at an early stage. First, 
it allows appropriate management to minimize harms; 
for example, the situation can be referred to a conflict Open Medicine 2010;4(1):e73
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of interest committee. The Institute of Medicine report 
Conflict of interest in medical research, education, and 
practice2 outlines steps for identifying and responding 
to such a committee. Second, it leads to more accurate 
reporting of fCOI. Investigators may be in an fCOI situ-
ation while they are conducting a study but divest them-
selves of it by the time they are submitting the study 
results for publication; such an fCOI may not be readily 
apparent to journal editors. The ICMJE recently pub-
lished a new disclosure form for competing interests that 
is completed by authors at the end of a study, during the 
publication phase.11 The form is used by journal editors, 
and consensus for the form’s use has been built among 
all ICMJE journals. Given that the disclosure is occur-
ring at the end of the research process, the opportunity 
to intervene and manage the fCOI is lost.  
The checklist may have an educational role in that it 
is designed to be completed by each investigator. We rec-
ognize that clinical research is generally conducted by a 
team of investigators. When all investigators are asked 
to complete the entire checklist, irrespective of their role 
in the study, they will become sensitized to important 
issues about their study. Academic policies do not always 
provide investigators with clear guidance to assist them 
in identifying and reporting situations that may be rel-
evant to fCOI. Further, national surveys of fCOI policies 
in academic settings suggest that these policies are often 
incomplete,6,  12, 13 fragmented12 and difficult for investiga-
tors to understand,12, 14 all of which limit their practical 
usability  by  investigators.  Although  the  checklist  will 
likely initially be completed by investigators only, it is 
also relevant to other study team members who may be 
affected by fCOI, such as study coordinators, research 
assistants and study nurses.  
 The checklist has been designed so that a completed 
version can be attached along with a completed CON-
SORT  checklist  in  the  setting  of  a  clinical  trial.15  The 
checklist  can  have  an  application  beyond  clinical  re-
search studies, and we anticipate that it will be adapted 
for use for other types of studies, such as basic science 
research. It can also be adapted for use outside of the 
research setting. For example, modified versions could 
be completed by grant review panel members making 
funding  decisions,  guideline  panel  members  making 
decisions about best practices, board members making 
decisions about the direction of an academic organiza-
tion, and by expert witnesses providing expert opinions 
in court proceedings or tribunals. Accordingly, we de-
signed the checklist with sections, modules and items so 
that it can be tailored for use in a range of settings.   
The checklist has limitations. First, our checklist was 
designed to focus exclusively on financial conflicts of in-
terest. We recognize that there are non-financial conflicts 
of interest, but these are known to be difficult to define.16 
Financial conflicts of interest are the most well recog-
nized and the most quantifiable.1 Second, although there 
are only 15 items, some users may feel daunted by the 
detail requested in a few of the sub-items. Our pilot test-
ing revealed a checklist completion time of less than 20 
minutes. Importantly, the entire checklist need not—and 
likely should not—be completed at one time. As we have 
recommended, different modules should be completed at 
different stages of the research. As users become more 
familiar with the checklist, and become aware of the in-
formation it compiles, the time required to complete it 
will likely decrease. In any case, the checklist can serve 
as a useful repository of essential administrative infor-
mation, and the time taken to complete the checklist may 
be considered a worthy investment in ensuring accurate 
and transparent disclosure of fCOI.
 
Conclusion
We developed the checklist to help investigators report 
comprehensive  structured  information  about  fCOI  to 
multiple stakeholder groups. We invite comments and 
suggestions for adaptations and improvement of the next 
iteration of the checklist at www.openmedicine.ca/fcoi- at www.openmedicine.ca/fcoi-
checklist. We also call for stakeholder groups to endorse 
the use of this checklist to improve transparency and 
mitigate fCOI in clinical research.  
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(Underlined terms are de￿  ned in the Glossary)
SECTION 1:   ADMINISTRATIVE INFORMATION
This section is completed at the study’s initiation and updated as necessary.
MODULE A:  ADMINISTRATIVE PROFILE
ITEM  DESCRIPTOR  RESPONSE
A.1.0  Study 
A.1.1  Study name                           
A.1.2  ❑ Single site or       ❑ multi-site 
A.1.3  Countries in which the data will be collected                             
A.1.4  Is this a clinical trial? 
A.1.4a  If you answered yes to item A.1.4:
    Is the study registered in a primary clinical trial registry that follows 
international standards developed by the World Health Organization and 
endorsed by the International Committee of Medical Journal Editors?  
   A list of approved registries can be found at 
http://www.who.int/ictrp/network/primary/en/index.html  
A.1.4b  What is the primary registry name and the registration number?                           
A.1.5  Name of the institution from which the study will be coordinated                           
A.1.6  Is any part of the study to be conducted by a contract research organization?
A.2.0  Investigator 
A.2.1  Name of the overall study o“   cial                           
A.2.2  Name of the investigator completing the checklist                           
A.2.3  What is your role in this research study? (check all that apply) 
A.2.3a  Principal investigator for the entire study 
A.2.3b  Principal investigator for a site or region 
A.2.3c  Co-investigator for the study 
A.2.3d  Paid consultant for the study 
A.2.3e  Member of steering committee 
A.2.3f  Participant recruiter 
A.2.3g  Other (please specify) 
Date the checklist section 1 was €  rst completed (day/month/year)                           
Date(s) the checklist section 1 was updated (day/month/year)                          
______________________________________
______________________________________
❑ Yes        ❑ No  
❑ Yes        ❑ No       ❑ Don’t know  
______________________________________
______________________________________
❑ Yes        ❑ No
______________________________________
______________________________________
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No




The Financial Con™  icts of Interest Checklist 2010 was 
designed to be completed by each investigator in 
the context of a speci￿  c clinical research study. 
As awareness of ￿  nancial con™  ict of interest issues 
grows, we see the checklist being completed by other 
study team members, such as study coordinators, 
research assistants and study nurses.  
This checklist contains four sections: administrative 
information, study information, personal ￿  nancial 
information, and authorship information. The 
investigator is expected to complete the checklist 
prospectively as the clinical research moves through 
its various stages. Sections 1, 2 and 3 are ￿  rst ￿  lled 
out at the study’s initiation, updated as required, and 
completed when the study manuscript is submitted for 
publication; section 4 is also completed at this time.  
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This section is completed at the study’s initiation and updated as necessary.
MODULE B:  FUNDER PROFILE
ITEM  DESCRIPTOR  RESPONSE
MODULE C:  CONTRACT PROFILE
ITEM  DESCRIPTOR  RESPONSE
B.1.0  Is this study funded? 
B.1.1  If you answered yes to item B.1.0, identify the type of funding support:
   ❑ Financial       ❑ Equipment        ❑ Test kit        ❑ Drug        ❑ Device       
  ❑ Other (please specify: ______________________________________)
B.1.2  List the funder(s) 
B.1.3  To which categories do/does the funder(s) belong? (check all that apply):
B.1.3a    Industry (e.g., pharmaceutical company, test or medical device 
company, biotech company) 
B.1.3b    Government funding agency (e.g., National Institutes of Health, 
Canadian Institutes of Health Research, Medical Research Council) 
B.1.3c    National or regional government body (e.g., National Health Service, 
Ministry of Health, Department of Defense) 
B.1.3d    Charitable foundation (e.g., American Heart Association, The Bill & 
Melinda Gates Foundation, Wellcome Trust) 
B.1.3e  Other(s) (please specify: ______________________________________)
C.1.0  Is there a contract with the funder(s)?
  (If you answered no or don’t know, skip to module D) 
  If you answered yes to item C.1.0, does your contract: 
C.1.1  include someone signing on behalf of your institution? 
C.1.2    require you to obtain additional funds for this research study from 
other sources? 
C.1.3    contain a clause that prohibits you from disclosing certain aspects about 
the study without the permission of the funder? 
C.1.4    specify the maximum allowable time for pre-publication review by 
the funder?  
C.1.4a  If you answered yes to item C.1.4, what is that time? 
❑ Yes        ❑ No       ❑ Don’t know
______________________________________
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No       ❑ Don’t know
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
______ days
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ITEM  DESCRIPTOR  RESPONSE
D.1.0    Who bears €  nal responsibility for and/or has ultimate 
authority over the following areas of the study? 
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know  
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know 
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know  
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know 
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know  
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know 
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
❑ Study team       ❑ Funder       ❑ Shared§       ❑ Don’t know
D.1.1  Conceptualizing and designing the study *†
D.1.2  Approving the ￿  nal design†   
D.1.3  Approving the ￿  nal data analysis plan 
D.1.4  Recruiting participants   
D.1.5  Collecting or assembling data*†   
D.1.6  Analyzing the data*†   
D.1.7  Interpreting the data*†   
D.1.8  Supervising or coordinating the study   
D.1.9    Deciding on the dissemination plan related to 
study results 
D.1.10    If the study is published, who bears ￿  nal respon-
sibility for and/or has ultimate authority over the 
following areas of the manuscript development?
D.1.10a  Drafting all or parts of the manuscript(s)*†
D.1.10b    Revising the manuscript(s) for important 
intellectual content*†   
D.1.10c    Giving ￿  nal approval of the version to be 
published*† 
D.1.10d    Deciding where the manuscript(s) will be 
submitted for publication†   
D.1.10e    Deciding the timing of the manuscript(s) 
submission for publication†  
D.1.10f  Deciding authorship   
D.1.10g  Deciding authorship order‡  
D.1.10h  Acting as the study guarantor‡   
D.1.10i    Providing administrative, technical or logistic 
support  
* Based on International Committee of Medical Journal Editors (ICMJE), II.A.1. Byline authors, Uniform requirements for manuscripts submitted to 
biomedical journals: writing and editing for biomedical publication (2008).1 This document describes the ICMJE’s three criteria for authorship. 
† Based on ICMJE, II.D.2. Potential con™  icts of interest related to project support, Uniform requirements for manuscripts submitted to biomedical journals: 
writing and editing for biomedical publication (2008).1  
‡ Based on World Association of Medical Editors (WAME), Policy statements: authorship.2 
§ Responsibility and/or authority are shared by the study team and the funder.
Date the checklist section 2 was €  rst completed (day/month/year)    ______________________________________                           
Date(s) the checklist section 2 was updated (day/month/year)    ______________________________________                           
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This section is completed at the study’s initiation and updated as necessary.
MODULE E:  FINANCIAL PROFILE
ITEM  DESCRIPTOR  RESPONSE
E.1.0  Does this study provide you with salary support? 
E.1.1    If you answered yes to item E.1.0, what percentage of your annual salary 
do you estimate will be obtained from the funder(s)? 
E.2.0    Will you personally receive direct or indirect €  nancial bene€  t for 
your role in this study? 
E.2.1  If you answered yes to item E.2.0, what is the amount?       
E.3.0    Will your department or institution receive or has it received 
€  nancial bene€  t (e.g., direct funding, gifts, general use or 
discretionary funds or any other payment above your 
institution’s standard administrative overhead rate) from 
the study funder(s)? (check all that apply) 
E.3.1  If you answered yes to item E.3.0, please specify the ￿  nancial bene￿  t: 
E.4.0    Does this study involve the commercialization of intellectual 
property (e.g., through patents, copyrights or royalties from 
such rights)? 
E.4.1    If you answered yes to item E.4.0, who receives the ￿  nancial bene￿  t from 
this commercialization? 
E.4.2    If you answered yes to item E.4.0, how is the intellectual property commer-
cialized (e.g., through patents, copyrights or royalties from such rights)?
E.5.0    Do you have any €  nancial interests related to competitor(s) of the 
funder(s) of your study? 
E.5.1  If you answered yes to item E.5.0, please specify: 
E.6.0    Do you currently have or expect to have any €  nancial interests 
related to the study funder(s)? 
E.6.1  If you answered yes to item E.6.0, please specify: 
E.7.0    Do any of your immediate family members (spouse or spouse 
equivalent, dependent child) currently have or expect to have any 
€  nancial interests related to the study funder(s)?   
E.7.1  If you answered yes to item E.7.0, please specify: 
      
                   
Date the checklist section 3 was €  rst completed (day/month/year)                           
Date(s) the checklist section 3 was updated (day/month/year)                           
❑ Yes        ❑ No
______ %
❑ Yes        ❑ No        ❑ Don’t know  
$ ______ 
❑ Yes, it does now   
❑ Yes, it has in the past   
❑ Yes, it will in the future   
❑ No  
❑ Don’t know  
______________________________________
❑ Yes        ❑ No        ❑ Don’t know
______________________________________
______________________________________
❑ Yes        ❑ No
______________________________________
❑ Yes        ❑ No        ❑ Don’t know
______________________________________
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______________________________________
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
❑ Yes        ❑ No
______________________________________
______________________________________
SECTION 4: AUTHORSHIP INFORMATION
This section is completed when a manuscript is being submitted for publication.
MODULE F:  AUTHORSHIP PROFILE
ITEM  DESCRIPTOR  RESPONSE
F.1.0  Is there a manuscript submitted for publication? 
F.1.1  If you answered yes to item F.1.0, what is the title of the manuscript? 
F.2.0  Are you an author on this manuscript? 
F.2.1    To which aspects of the study and the manuscript development did you 
make a substantial contribution?  
F.2.1a  Obtaining funding‡ 
F.2.1b  Conceptualizing and designing the study* 
F.2.1c  Providing study materials and/or recruiting participants‡
F.2.1d  Collecting or assembling data* 
F.2.1e  Analyzing and interpreting data* 
F.2.1f  Providing statistical expertise‡ 
F.2.1g  Supervising or coordinating the study‡ 
F.2.1h  Drafting all or part of the manuscript* 
F.2.1i  Revising the manuscript for important intellectual content* 
F.2.1j  Giving ￿  nal approval of the version to be published* 
F.2.1k  Providing administrative, technical or logistic support‡ 
F.2.2  Are you the study guarantor?† 
F.3.0  Are you aware of the involvement of a guest or ghost author?†
* Based on ICMJE, II.A.1. Byline authors, Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for 
biomedical publication (2008).1 This document describes the ICMJE’s three criteria for authorship.
† Based on WAME, Policy statements: authorship.2 
‡ Derived from the JAMA Authorship responsibility, ￿  nancial disclosure, acknowledgment, and copyright transfer/publishing agreement;3 
some are also mentioned in ICMJE1 and WAME2 
Date the checklist section 4 was €  rst completed (day/month/year)                           
Date(s) the checklist section 4 was updated (day/month/year)                           
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Authorship    “  An ‘author’ is generally considered to be someone who has made substantive intellectual contributions to a 
published study.” 
  – International Committee of Medical Journal Editors1
Authorship order    “  Many di³  erent ways of determining order of authorship exist across disciplines, research groups, and countries. 
Examples of authorship policies include descending order of contribution, placing the person who took the 
lead in writing the manuscript or doing the research ￿  rst and the most experienced contributor last, and 
alphabetical or random order. While the signi￿  cance of a particular order may be understood in a given setting, 
order of authorship has no generally agreed upon meaning.”
  – Faculty of Medicine Harvard Medical School4
Clinical trial  “  Research study that prospectively assigns human participants or groups of humans to one or more health-
related interventions to evaluate the e³  ects on health outcomes”
  – World Health Organization5
Clinical trial registry  “  The [online] entity that houses the clinical trial register. It is responsible for ensuring the completeness and 
accuracy of the information the register contains, and that the registered information [can be] used to inform 
health care decision making.”
  – World Health Organization5
Contract  “  A document, dated and signed by the investigator, institution and sponsor, that sets out any agreements on 
￿  nancial matters and delegation/distribution of responsibilities. The protocol may also serve as a contract when 
it contains such information and is signed.”
  – Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products6
Contract research organization 
  “  A scienti￿  c organization (commercial, academic or other) to which a sponsor may transfer some of its tasks and 
obligations [related to a clinical trial]. Any such transfer should be de￿  ned in writing.”
  – Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products6
Dissemination plan  “  Speci￿  c details on how information or knowledge gained from a project is distributed and shared. Project 
dissemination can occur through presentations, conferences, publications and web sites.”
  – Human Resources and Skills Development Canada7
Financial interest  Anything of monetary value, including but not limited to:
  • Salary or other payments for services
  [Examples include: 
    • Payment for serving as a speaker or on a speaker’s bureau
    • Payment for serving on an advisory board 
    • Payment for enrolling patients in clinical trials 
    • Payment for travel expenses for attending conferences
    • Payment for expert testimony for the funder] 
  •   Equity interests (e.g., stocks, stock options) [Other examples include commercial business interests such as 
ownerships, partnerships, joint ventures])
  • Intellectual property rights (e.g., patents, copyrights and royalties from such rights) 
  – U.S. Public Health Service8
Funder  “  [Organization] providing [the ￿  nancial or monetary support] for the study through contracts, grants or 
donations to an authorized member of either the employing and/or care [organization]”
  – The University of She”   eld9
Ghost author  “  Ghost authorship exists when someone has made substantial contributions to writing a manuscript and this 
role is not mentioned in the manuscript itself.”
  – World Association of Medical Editors10
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Open Medicine 2010;4(1):e80Guarantor  “  The person who takes responsibility for the integrity of the work as a whole, from inception to published 
article, and publishes that information”
  – International Committee of Medical Journal Editors1
Guest author  “  Guest authorship is the practice of inviting those whose contribution has been scienti￿  cally trivial to be 
coauthors, as payment for a service (e.g. referral of a patient) or as tribute (e.g., homage to a department 
head). The practice of guest authorship is deceptive because the ‘authors’ so named gather credit without 
being able to account for the work.”
  – Rennie et al.11
Overall study oŸ   cial  “Person(s) responsible for the overall scienti￿  c leadership of the protocol, including study principal
     investigator”
  – ClinicalTrials.gov12 
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Table 2:  Example document for the Financial Conflicts of Interest 
Checklist 2010
(Underlined terms are defined in the Glossary)
SECTION 1:   ADMINISTRATIVE INFORMATION
This section is completed at the study’s initiation and updated as necessary.
MODULE A:  ADMINISTRATIVE PROFILE
ITEM  DESCRIPTOR  EXAMPLE
A.1.0  Study 
A.1.1  Study name                           
A.1.2  q Single site or       q multi-site 
A.1.3  Countries in which the data will be collected                             
A.1.4  Is this a clinical trial? 
A.1.4a  If you answered yes to item A.1.4:
    Is the study registered in a primary clinical trial registry that follows 
international standards developed by the World Health Organization and 
endorsed by the International Committee of Medical Journal Editors?  
  Alistofapprovedregistriescanbefoundat
http://www.who.int/ictrp/network/primary/en/index.html 
A.1.4b  What is the primary registry name and the registration number?                           
A.1.5  Name of the institution from which the study will be coordinated                           
A.1.6  Is any part of the study to be conducted by a contract research organization?
A.2.0  Investigator 
A.2.1  Name of the overall study official                           
A.2.2  Name of the investigator completing the checklist                           
A.2.3  What is your role in this research study? (check all that apply) 
A.2.3a  Principal investigator for the entire study 
A.2.3b  Principal investigator for a site or region 
A.2.3c  Co-investigator for the study 
A.2.3d  Paid consultant for the study 
A.2.3e  Member of steering committee 
A.2.3f  Participant recruiter 
A.2.3g  Other (please specify) 
Date the checklist section 1 was first completed (day/month/year)                           




q Yes        q No  
 
q Yes        q No       q Don’t know  
______________________________________
______________________________________




q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No




The example document is completed using a fictitious 
investigator and a fictitious study.  
This fictitious example shows how the checklist  
is meant to be completed in a prospective manner  
by an individual investigator. Although there are  
excellent examples of financial conflict of interest 
reporting in the medical literature, these are done in 
a retrospective manner and usually relate to groups 
of authors. The example document we provide is for 
illustrative purposes only and is not meant to describe 
preferred practice.
Drug A versus Drug B for pneumonia in adults: 
multicentre randomized controlled trial
ISRCTN.org and ISRCTN12345678
The Fictitious Institute of Fictitious Hospital, Toronto, Canada




example Document                                                                                                                    Rochon et al. Financial Conflicts of Interest Checklist 2010                                                                     Rochon et al.
SECTION 2: STUDY INFORMATION
This section is completed at the study’s initiation and updated as necessary.
MODULE B:  FUNDER PROFILE
ITEM  DESCRIPTOR  EXAMPLE
MODULE C:  CONTRACT PROFILE
ITEM  DESCRIPTOR  EXAMPLE
B.1.0  Is this study funded? 
B.1.1  If you answered yes to item B.1.0, identify the type of funding support:
   q Financial       q Equipment        q Test kit        q Drug        q Device       
  q Other (please specify: ______________________________________)
B.1.2  List the funder(s) 
B.1.3  To which categories do/does the funder(s) belong? (check all that apply):
B.1.3a    Industry (e.g., pharmaceutical company, test or medical device 
company, biotech company) 
B.1.3b    Government funding agency (e.g., National Institutes of Health, 
Canadian Institutes of Health Research, Medical Research Council) 
B.1.3c    National or regional government body (e.g., National Health Service, 
Ministry of Health, Department of Defense) 
B.1.3d    Charitable foundation (e.g., American Heart Association, The Bill & 
Melinda Gates Foundation, Wellcome Trust) 
B.1.3e  Other(s) (please specify: ______________________________________)
C.1.0  Is there a contract with the funder(s)?
  (If you answered no or don’t know, skip to module D) 
  If you answered yes to item C.1.0, does your contract: 
C.1.1  include someone signing on behalf of your institution? 
C.1.2    require you to obtain additional funds for this research study from  
other sources? 
C.1.3    contain a clause that prohibits you from disclosing certain aspects about 
the study without the permission of the funder? 
C.1.4    specify the maximum allowable time for pre-publication review by  
the funder?  
C.1.4a  If you answered yes to item C.1.4, what is that time? 
q Yes        q No       q Don’t know
______________________________________
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No       q Don’t know
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
______ days
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MODULE D: STUDY TEAM AND FUNDER RELATIONSHIP PROFILE 
ITEM  DESCRIPTOR  EXAMPLE
D.1.0    Who bears final responsibility for and/or has ultimate 
authority over the following areas of the study? 
q Study team       q Funder       q Shared§       q Don’t know  
q Study team       q Funder       q Shared§       q Don’t know 
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know  
q Study team       q Funder       q Shared§       q Don’t know 
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know  
q Study team       q Funder       q Shared§       q Don’t know 
q Study team       q Funder       q Shared§       q Don’t know
             
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
q Study team       q Funder       q Shared§       q Don’t know
D.1.1  Conceptualizing and designing the study *†
D.1.2  Approving the final design†   
D.1.3  Approving the final data analysis plan 
D.1.4  Recruiting participants   
D.1.5  Collecting or assembling data*†   
D.1.6  Analyzing the data*†   
D.1.7  Interpreting the data*†   
D.1.8  Supervising or coordinating the study   
D.1.9    Deciding on the dissemination plan related to 
study results 
D.1.10    If the study is published, who bears final respon-
sibility for and/or has ultimate authority over the 
following areas of the manuscript development?
D.1.10a  Drafting all or parts of the manuscript(s)*†
D.1.10b    Revising the manuscript(s) for important 
intellectual content*†   
D.1.10c    Giving final approval of the version to be 
published*† 
D.1.10d    Deciding where the manuscript(s) will be 
submitted for publication†   
D.1.10e    Deciding the timing of the manuscript(s) 
submission for publication†  
D.1.10f  Deciding authorship   
D.1.10g  Deciding authorship order‡  
D.1.10h  Acting as the study guarantor‡   
D.1.10i    Providing administrative, technical or logistic 
support  
* Based on International Committee of Medical Journal Editors (ICMJE), II.A.1. Byline authors, Uniformrequirementsformanuscriptssubmittedto
biomedicaljournals:writingandeditingforbiomedicalpublication (2008).1 This document describes the ICMJE’s three criteria for authorship. 
† Based on ICMJE, II.D.2. Potential conflicts of interest related to project support, Uniformrequirementsformanuscriptssubmittedtobiomedicaljournals:
writingandeditingforbiomedicalpublication (2008).1  
‡ Based on World Association of Medical Editors (WAME), Policy statements: authorship.2 
§ Responsibility and/or authority are shared by the study team and the funder.
Date the checklist section 2 was first completed (day/month/year)    ______________________________________                           
Date(s) the checklist section 2 was updated (day/month/year)    ______________________________________                           
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SECTION 3: PERSONAL FINANCIAL INFORMATION
This section is completed at the study’s initiation and updated as necessary.
MODULE E:  FINANCIAL PROFILE
ITEM  DESCRIPTOR  EXAMPLE
E.1.0  Does this study provide you with salary support? 
E.1.1    If you answered yes to item E.1.0, what percentage of your annual salary 
do you estimate will be obtained from the funder(s)? 
E.2.0    Will you personally receive direct or indirect financial benefit for 
your role in this study? 
E.2.1  If you answered yes to item E.2.0, what is the amount?       
E.3.0    Will your department or institution receive or has it received 
financial benefit (e.g., direct funding, gifts, general use or  
discretionary funds or any other payment above your  
institution’s standard administrative overhead rate) from  
the study funder(s)? (check all that apply) 
E.3.1  If you answered yes to item E.3.0, please specify the financial benefit: 
E.4.0    Does this study involve the commercialization of intellectual  
property (e.g., through patents, copyrights or royalties from  
such rights)? 
E.4.1    If you answered yes to item E.4.0, who receives the financial benefit from 
this commercialization? 
E.4.2    If you answered yes to item E.4.0, how is the intellectual property commer-
cialized (e.g., through patents, copyrights or royalties from such rights)?
E.5.0    Do you have any financial interests related to competitor(s) of the 
funder(s) of your study? 
E.5.1  If you answered yes to item E.5.0, please specify: 
E.6.0    Do you currently have or expect to have any financial interests 
related to the study funder(s)? 
E.6.1  If you answered yes to item E.6.0, please specify: 
E.7.0    Do any of your immediate family members (spouse or spouse 
equivalent, dependent child) currently have or expect to have any 
financial interests related to the study funder(s)?   
E.7.1  If you answered yes to item E.7.0, please specify: 
      
                   
Date the checklist section 3 was first completed (day/month/year)                           
Date(s) the checklist section 3 was updated (day/month/year)                           
q Yes        q No
______ %
q Yes        q No        q Don’t know  
$ ______ 
q Yes, it does now   
q Yes, it has in the past   
q Yes, it will in the future   
q No  
q Don’t know  
______________________________________
 q Yes        q No        q Don’t know
______________________________________
______________________________________
q Yes        q No
______________________________________
q Yes        q No        q Don’t know
______________________________________
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q Yes        q No
______________________________________
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
q Yes        q No
______________________________________
______________________________________
SECTION 4: AUTHORSHIP INFORMATION
This section is completed when a manuscript is being submitted for publication.
MODULE F:  AUTHORSHIP PROFILE
ITEM  DESCRIPTOR  EXAMPLE
F.1.0  Is there a manuscript submitted for publication? 
F.1.1  If you answered yes to item F.1.0, what is the title of the manuscript? 
F.2.0  Are you an author on this manuscript? 
F.2.1    To which aspects of the study and the manuscript development did you 
make a substantial contribution?  
F.2.1a  Obtaining funding‡ 
F.2.1b  Conceptualizing and designing the study* 
F.2.1c  Providing study materials and/or recruiting participants‡
F.2.1d  Collecting or assembling data* 
F.2.1e  Analyzing and interpreting data* 
F.2.1f  Providing statistical expertise‡ 
F.2.1g  Supervising or coordinating the study‡ 
F.2.1h  Drafting all or part of the manuscript* 
F.2.1i  Revising the manuscript for important intellectual content* 
F.2.1j  Giving final approval of the version to be published* 
F.2.1k  Providing administrative, technical or logistic support‡ 
F.2.2  Are you the study guarantor?† 
F.3.0  Are you aware of the involvement of a guest or ghost author?†
* Based on ICMJE, II.A.1. Byline authors, Uniformrequirementsformanuscriptssubmittedtobiomedicaljournals:writingandeditingfor
biomedicalpublication(2008).1 This document describes the ICMJE’s three criteria for authorship.
† Based on WAME, Policy statements: authorship.2 
‡ Derived from the JAMA Authorship responsibility, financial disclosure, acknowledgment, and copyright transfer/publishing agreement;3 
some are also mentioned in ICMJE1 and WAME2 
Date the checklist section 4 was first completed (day/month/year)                           
Date(s) the checklist section 4 was updated (day/month/year)                           
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GLOSSARY 
Authorship    “  An ‘author’ is generally considered to be someone who has made substantive intellectual contributions to a 
published study.” 
  – InternationalCommitteeofMedicalJournalEditors1
Authorship order    “  Many different ways of determining order of authorship exist across disciplines, research groups, and countries. 
Examples of authorship policies include descending order of contribution, placing the person who took the 
lead in writing the manuscript or doing the research first and the most experienced contributor last, and 
alphabetical or random order. While the significance of a particular order may be understood in a given setting, 
order of authorship has no generally agreed upon meaning.”
  – FacultyofMedicineHarvardMedicalSchool4
Clinical trial  “  Research study that prospectively assigns human participants or groups of humans to one or more health-
related interventions to evaluate the effects on health outcomes”
  – WorldHealthOrganization5
Clinical trial registry  “  The [online] entity that houses the clinical trial register. It is responsible for ensuring the completeness and 
accuracy of the information the register contains, and that the registered information [can be] used to inform 
health care decision making.”
  – WorldHealthOrganization5
Contract  “  A document, dated and signed by the investigator, institution and sponsor, that sets out any agreements on 
financial matters and delegation/distribution of responsibilities. The protocol may also serve as a contract when 
it contains such information and is signed.”
  – GuidelinesforGoodClinicalPractice(GCP)forTrialsonPharmaceuticalProducts6
Contract research organization 
  “  A scientific organization (commercial, academic or other) to which a sponsor may transfer some of its tasks and 
obligations [related to a clinical trial]. Any such transfer should be defined in writing.”
  – GuidelinesforGoodClinicalPractice(GCP)forTrialsonPharmaceuticalProducts6
Dissemination plan  “  Specific details on how information or knowledge gained from a project is distributed and shared. Project 
dissemination can occur through presentations, conferences, publications and web sites.”
  – HumanResourcesandSkillsDevelopmentCanada7
Financial interest  Anything of monetary value, including but not limited to:
  • Salary or other payments for services
  [Examples include: 
    • Payment for serving as a speaker or on a speaker’s bureau
    • Payment for serving on an advisory board 
    • Payment for enrolling patients in clinical trials 
    • Payment for travel expenses for attending conferences
    • Payment for expert testimony for the funder] 
  •   Equity interests (e.g., stocks, stock options) [Other examples include commercial business interests such as 
ownerships, partnerships, joint ventures])
  • Intellectual property rights (e.g., patents, copyrights and royalties from such rights) 
  – U.S.PublicHealthService8
Funder  “  [Organization] providing [the financial or monetary support] for the study through contracts, grants or 
donations to an authorized member of either the employing and/or care [organization]”
  – TheUniversityofSheffield9
Ghost author  “  Ghost authorship exists when someone has made substantial contributions to writing a manuscript and this 
role is not mentioned in the manuscript itself.”
  – WorldAssociationofMedicalEditors10
Open Medicine 2010;4(1):e87Open Medicine 2010;4(1):e88
Example Document                                                                                                                   Rochon et al. Financial Conflicts of Interest Checklist 2010                                                                     Rochon et al.
Guarantor  “  The person who takes responsibility for the integrity of the work as a whole, from inception to published 
article, and publishes that information”
  –InternationalCommitteeofMedicalJournalEditors1
Guest author  “  Guest authorship is the practice of inviting those whose contribution has been scientifically trivial to be 
coauthors, as payment for a service (e.g. referral of a patient) or as tribute (e.g., homage to a department 
head). The practice of guest authorship is deceptive because the ‘authors’ so named gather credit without 
being able to account for the work.”
  – Rennieetal.11
Overall study official  “Person(s) responsible for the overall scientific leadership of the protocol, including study principal
     investigator”
  – ClinicalTrials.gov12 
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Box 1: Explanation document for the Financial Confl  icts of Interest Checklist 2010 
INTRODUCTION
The Financial Con￿  icts of Interest Checklist 2010 was designed to be completed by each investigator in the context of a speci…  c 
clinical research study. As awareness of …  nancial con￿  ict of interest (fCOI) issues grows, we see the checklist being completed by 
other study team members, such as study coordinators, research assistants and study nurses. 
This checklist contains four sections: administrative information, study information, personal ￿  nancial information, and authorship 
information. The investigator is expected to complete the checklist prospectively as the clinical research moves through its various 
stages. Sections 1, 2 and 3 are ￿  rst ￿  lled out at the study’s initiation, updated as required, and completed when the study manuscript 
is submitted for publication; section 4 is also completed at this time. 
SECTION 1: ADMINISTRATIVE INFORMATION
This section is completed at the study’s initiation and updated as necessary
This module compiles administrative information about the study and the investigator …  lling out the checklist. Administrative 
information helps characterize the study and place it in context. 
Identifying the countries involved in data collection for a speci￿  c clinical trial provides an opportunity to evaluate the standards in 
place for the ethical conduct of trials across sites.1,2 
Information about clinical trial registration is included to promote accountability and transparency of research. Trial registration helps 
mitigate the potential impact of fCOI by publicly documenting important protocol information before a study begins and participants 
are enrolled. Two decades ago Chalmers described the serious problem of underreporting of clinical trials that occurs when results are 
either published in insu“   cient detail or not published at all, and he advocated for trial registration.3 A more recent systematic review 
has shown that underreporting of clinical trials continues to be an issue.4 This has important implications for clinical practice because 
it means that the body of published articles may exaggerate the e³  ectiveness of a given therapy. 
The International Committee of Medical Journal Editors (ICMJE) requires registration for trials published in journals that adhere to 
ICMJE standards.5 The World Health Organization’s International Clinical Trials Registry Platform was established in 2005 to create 
global standards for trial registration.6 Further, trial registration and results reporting are now required by law in the United States.7
Information is requested about the role that each individual completing the checklist will play in the study’s conduct. This informs 
stakeholders about the extent to which he or she is involved in the study and provides a perspective on the level of knowledge and 
responsibility the investigator will have of the study. An overall study o“   cial will have a comprehensive understanding of all of the 
key issues related to the organization of the study. Other investigators may have more limited knowledge about certain aspects 
of the study. 
SECTION 2: STUDY INFORMATION
This section is completed at the study’s initiation and updated as necessary
Module B:  Funder Pro…  le
This module compiles information about all of the sources of funding for the study.  
Research studies receive funding from di³  erent sources. Information in this module is requested about funders from categories 
including industry, government, charitable foundations and others.  Financial con™  icts of interest can occur with a range of di³  erent 
funders. Con™  icts of interest related to the conditions of the funding have the potential to in™  uence research ￿  ndings.8,9 Industry 
funding is important to consider because 70% of clinical drug trial funding in the US is estimated to be from industry sources,10 and a 
quarter of academic investigators in biomedical research are estimated to receive industry funding for their research.11 Accordingly, 
reporting of funding sources is relevant in assessing possible fCOI.
Module C:  Contract Pro…  le
This module addresses contracts with funders and is …  lled out by investigators who have received a contract for the study. 
Contracts vary depending on the institution, the nature of the study, and the funder. Considerable concern has been expressed about 
restrictive con￿  dentiality clauses,12,13,14 which can be used to delay or prevent study information from being made public and thereby 
interfere with the publication of negative results or unfavourable data.14  
Investigators need to retain the right to decide on publication of the study results to ensure that the study results contribute to 
publicly available knowledge. ICMJE supports the sponsor’s right to review a manuscript before it is published but suggests a de￿  ned 
time of 30–60 days to allow for the ￿  ling of additional patent protection.15 One academic organization suggests extending the time to 
90 days, and in exceptional cases to as long as 6 months.12   
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Module D: Study Team and Funder Relationship Pro…  le
This module explores the relationship between the study team and the funder and identi…  es who bears …  nal responsibility for 
and authority over study conduct and manuscript development activities that are susceptible to fCOI. 
An fCOI exists when a funder controls key study elements that can in™  uence the validity and dissemination of results.16 In its 
Uniform Requirements for Manuscripts Submitted to Biomedical Journals, ICMJE states that “Authors should describe the role of the 
study sponsor, if any, in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit 
the report for publication.”8 Funders should not have sole control over the data or decisions to publish.15  
In ￿  lling out the response options (study team, funder, shared, don’t know), investigators describe the relationship between the study 
team and the funder.    
SECTION 3: PERSONAL FINANCIAL INFORMATION
This section is completed at the study’s initiation and updated as necessary
Module E:  Financial Pro…  le
This module compiles information related to the disclosure of …  nancial relationships in order to create a …  nancial pro…  le. The 
information requested pertains to funding that the individual and his or her institution may receive. 
When an investigator stands to gain ￿  nancially from the research, this may bias their judgment about the study conduct and 
manuscript development. The in™  uence that ￿  nancial reward may have on investigators’ judgment and behaviour has been the 
subject of much discussion. Recommendations have been made related to the reporting of ￿  nancial interests by investigators.17 
These are consistent with the United States Public Health Service regulations.18 Social science research suggests that any gift has 
the potential to create an fCOI.19 This ￿  nding is important because research-related gifts are common. In a study using a sample 
of researchers receiving federal funds, some 43% reported receiving research-related gifts from commercial entities.20  When an 
institution stands to gain ￿  nancially from the research conducted by its investigators, this creates the potential for institutional fCOI. 
Left unmanaged, institutional fCOI could misdirect research agendas. Financial con™  icts of interest can also occur in relation  to 
competitors, who have a vested interest in having their product perform better than the comparison product. 
Partnerships between funders and academia can lead to institutional fCOI. Funded clinical trials generally provide academic 
institutions with ￿  nancial compensation for administering or participating in trials. In some cases they may receive payment above 
the institution’s standard administrative overhead charges. 
Research discoveries can lead to commercialization of intellectual property and generate revenue, thereby creating potential for both 
investigator and institutional fCOI in the intellectual property.21 
Although fCOI is usually thought of in the context of the investigator, it is also important to consider relationships their immediate 
family members may have with funders.
SECTION 4: AUTHORSHIP INFORMATION
This section is completed when a manuscript is being submitted for publication.  
Module F:  Authorship Pro…  le
This module compiles authorship information, but it should be completed by all investigators, even if they are not listed as authors, 
since it provides the opportunity to identify the contributions of each investigator leading to publication.
When a study is published, it is essential that readers have a clear understanding of the roles that the authors played when conducting 
the study and preparing the manuscript. Accurate and transparent reporting of all of the contributions to a published article establishes 
accountability, responsibility and appropriate credit for scienti￿  c work.22 
Module F contains items that are based on the ICMJE Uniform requirements criteria for authorship credit.8 The three criteria for 
authorship are “1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) 
drafting the article or revising it critically for important intellectual content; and 3) ￿  nal approval of the version to be published.” These 
criteria have been widely accepted by organizations including WAME22 and Consolidated Standards of Reporting Trials (CONSORT).23  
Investigators can contribute to the development of a manuscript in ways that are not encompassed by the three ICMJE authorship 
criteria. These roles include obtaining funding, providing study materials and/or recruiting participants, providing statistical expertise, 
supervising or coordinating the study, and providing administrative, technical or logistic support
In its criteria for authorship, WAME discusses guest or ghost authors, stating that it is dishonest not to mention someone who wrote 
part of the manuscript (i.e., a ghost author) or to include investigators as authors only because of their reputation (i.e., a guest author).22 
Ghost authorship needs to be acknowledged as this involvement has the potential to bias the presentation of research ￿  ndings.24 An 
item related to these practices is included in the checklist, and de￿  nitions are provided in the glossary.
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